Economic Indicators - The Dallas Fed manufacturing activity survey for September unexpectedly fell by -6.9 to -8.7, weaker than expectations of an increase to -1.0 [1] - US pending home sales for August rose by +4.0% month-over-month, significantly stronger than expectations of +0.4% and marking the largest increase in five months [2] - The S&P companies are expected to post +6.9% earnings growth in Q3, up from +6.7% as of the end of May, with over 22% of companies providing guidance expected to beat analysts' expectations [8] Stock Market Performance - Stock indexes experienced a rally, with the S&P 500, Dow Jones Industrial Average, and Nasdaq 100 reaching record highs last week, driven by strong earnings growth and Fed easing measures [4] - On Monday, the S&P 500 Index closed up +0.26%, the Dow Jones closed up +0.15%, and the Nasdaq 100 closed up +0.44% [6] - Chipmakers led technology stocks higher, with GlobalFoundries and Micron Technology closing up more than +3% [14] Interest Rates and Bond Market - The 10-year T-note yield fell by -3 bp to 4.14%, influenced by expectations of weak labor market news prompting the Fed to continue cutting interest rates [5][11] - The 10-year breakeven inflation rate fell to a 1.5-week low of 2.357%, supporting Fed policy and T-note prices [11] Corporate Developments - Merus NV closed up more than +35% after Genmab announced a deal to acquire the company for $8 billion or $97 per share [16] - Electronic Arts closed up more than +4% after a consortium acquired the company for $55 billion or $210 per share [18] - Western Digital closed up more than +9% after an upgrade from Rosenblatt Securities, raising its target on the stock to $125 from $90 [16] Sector Performance - Energy producers retreated after WTI crude oil prices fell by more than -3%, with companies like Diamondback Energy and Devon Energy closing down more than -3% [15] - Rising corporate earnings expectations provide a bullish backdrop for stocks, with significant positive guidance from S&P 500 companies [8]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [1][2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Viewpoint - MoonLake Immunotherapeutics' stock price plummeted over 90% following the release of disappointing week-16 results from its Phase 3 VELA-1 and VELA-2 trials for sonelokimab, despite achieving statistical significance in primary and secondary endpoints [1][8]. Group 1: Trial Design and Results - A total of 838 patients were enrolled in the VELA trials, which compared a single 120mg dose of sonelokimab to placebo, with primary endpoint HiSCR75 assessed at week 16 [2]. - Both VELA-1 and VELA-2 trials achieved statistical significance for all key endpoints, including lesion counts and patient-reported outcomes, with p-values below 0.001 [3]. - Sonelokimab showed a statistically significant HiSCR75 response as early as week 4 in both studies [3]. Group 2: Efficacy and Patient Outcomes - At week 16, 34.8% of patients in VELA-1 and 35.9% in VELA-2 achieved HiSCR75, while placebo response rates were 17.5% and 25.6%, respectively [5]. - Approximately 30% of patients reported a significant reduction in pain, with at least a 3-point improvement in the worst pain NRS in both trials [6]. - Nearly 60% of patients experienced a meaningful improvement of 4 points or more in the Dermatology Quality of Life Index (DLQI), representing a 20 percentage-point benefit over baseline [7]. Group 3: Safety and Future Outlook - The safety profile of sonelokimab remained favorable, consistent with previous studies, and no new safety signals were reported [7]. - Preliminary analyses indicate that responses may continue to improve beyond week 16, with placebo patients achieving similar responses to those initially randomized to sonelokimab by week 20 [4].

Company Earnings - Carnival (NYSE: CCL) reported third-quarter earnings of $1.43 per share, exceeding the analyst consensus estimate of $1.32 per share [2] - The company also reported quarterly sales of $8.153 billion, surpassing the analyst consensus estimate of $8.101 billion [2] Stock Movements - Tilray Brands, Inc. (NASDAQ: TLRY) shares increased by 40% to $1.6050 following a video from President Donald Trump promoting cannabis health benefits [8] - Merus N.V. (NASDAQ: MRUS) shares surged 36% to $93.93 after Genmab agreed to acquire the company for $97 per share [8] - Better Home & Finance Holding Company (NASDAQ: BETR) shares rose 17% to $62.23 after announcing a $75 million at-the-market offering for Class A shares [8] - KALA BIO, Inc. (NASDAQ: KALA) shares plummeted 89% to $2.15 after failing to meet primary endpoints in a clinical trial [8] - MoonLake Immunotherapeutics (NASDAQ: MLTX) shares fell 89% to $6.69 due to a failed trial [8] - IO Biotech, Inc. (NASDAQ: IOBT) shares dropped 78% to $0.3501 following an update after a pre-BLA meeting with the FDA [8] Economic Indicators - U.S. pending home sales surged by 4% in August, marking the sharpest gain in five months, compared to a 0.4% decline in the previous month [10] - The Dallas Fed's general business activity index for Texas manufacturing declined to -8.7 in September from -1.7 in the previous month [10]

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential claims by Faruqi & Faruqi, LLP, a prominent national securities law firm [1] Group 1 - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [1] - The investigation pertains to potential claims against MoonLake Immunotherapeutics, which is listed on NASDAQ under the ticker MLTX [1]

A potential negative factor for market sentiment is the likelihood that the US government will shut down on Wednesday if lawmakers fail to pass a spending bill or continuing resolution (CR) by then. Congressional leaders are scheduled to meet with President Trump later today to negotiate a short-term spending bill. The White House warned last Wednesday that a shutdown would trigger widespread dismissals of employees in government programs that don’t align with President Trump’s priorities.Comments today fro ...

Core Insights - MoonLake Immunotherapeutics' shares dropped over 85% in pre-market trading on September 29 due to disappointing Phase 3 VELA trial results, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [2] - The Phase 3 data is considered inadequate compared to the previously reported Phase 2 MIRA trial results and is lagging behind competing drugs, raising concerns about the drug's commercial viability [2] - Block & Leviton is investigating potential securities law violations related to MoonLake's public statements about its drug trials [4] Company Overview - MoonLake Immunotherapeutics is a company involved in drug development, specifically in immunotherapeutics [2] - The company had previously highlighted positive results from its Phase 2 MIRA trial, which are now being overshadowed by the Phase 3 results [2] Legal Investigation - Block & Leviton is actively investigating whether MoonLake Immunotherapeutics committed securities law violations and may file actions to recover losses for affected investors [4] - Investors who have lost money on their MoonLake investments are encouraged to contact Block & Leviton for potential recovery options [5] Investor Eligibility - Any investor who purchased common stock of MoonLake Immunotherapeutics and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their shares [3] Whistleblower Information - Individuals with non-public information about MoonLake Immunotherapeutics are encouraged to assist in the investigation or report to the Securities Exchange Commission under the whistleblower program, with potential rewards for original information [6]

Core Viewpoint - MoonLake, a biotechnology company, experienced a significant stock drop of 89% after disappointing Phase III clinical trial results for its drug sonelokimab, leading to drastic reductions in target prices by major banks [2][5][6]. Group 1: Company Performance - MoonLake's market capitalization fell from approximately $3.98 billion to under $500 million following the trial results [7]. - The drug sonelokimab showed a response rate of 35% and 36% in two trials, compared to 18% and 26% in the placebo groups, which analysts deemed underwhelming [5][6]. - Analysts from Stifel and RBC downgraded MoonLake's ratings and target prices significantly, with Stifel lowering its target from $77 to $13 and RBC from $67 to $10 [6][7]. Group 2: Market Reaction - Following the announcement, UCB SA, a competitor, saw its stock rise over 20%, benefiting from MoonLake's poor results [7]. - The market for hidradenitis suppurativa (HS), which sonelokimab targets, is projected to grow from $2 billion to $15 billion by 2035, indicating potential for future competition [7]. Group 3: Acquisition Interest - Earlier in June, Merck had made a non-binding offer exceeding $3 billion for MoonLake, which was rejected, highlighting MoonLake's strong negotiating position at that time [8]. - Merck is actively seeking to diversify its revenue sources as its blockbuster drug Keytruda faces patent expiration in 2028 [9].

Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining around 150 points on Monday [1] - The Dow rose 0.19% to 46,333.68, the NASDAQ increased 0.67% to 22,635.76, and the S&P 500 climbed 0.42% to 6,671.51 [1] - Information technology shares jumped by 0.8%, while energy stocks fell by 0.8% [1] Real Estate Sector - U.S. pending home sales surged by 4% in August, marking the sharpest gain in five months, compared to a 0.4% decline in the previous month [2][7] Commodity Market - Oil traded down 2% to $64.41, while gold rose 0.9% to $3,844.30 [4] - Silver increased by 0.5% to $46.895, and copper rose 0.7% to $4.8070 [4] European Market - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2% [5] - Spain's IBEX 35 Index fell 0.2%, London's FTSE 100 rose 0.4%, Germany's DAX 40 slipped 0.1%, and France's CAC 40 climbed 0.3% [5] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng gaining 1.89%, China's Shanghai Composite rising 0.90%, and India's BSE Sensex falling 0.08% [6] Stock Movements - Maison Solutions Inc. shares surged 257% to $3.3603, while Predictive Oncology Inc. shares rose 112% to $1.64 after a reverse stock split [9] - Maison Solutions Inc. shares also gained 167% to $2.56 [9] - KALA BIO, Inc. shares dropped 92% to $1.4350 after failing to meet primary endpoints in a clinical trial [9] - MoonLake Immunotherapeutics shares fell 89% to $6.76 following disappointing trial results [9] - IO Biotech, Inc. shares decreased 75% to $0.3941 after an update post-FDA meeting [9]

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining around 150 points on Monday, while the Dow rose 0.19% to 46,333.68, the NASDAQ increased 0.67% to 22,635.76, and the S&P 500 climbed 0.42% to 6,671.51 [1] - Information technology shares jumped by 0.8%, while energy stocks fell by 0.8% [1] Real Estate Sector - U.S. pending home sales surged by 4% in August, marking the sharpest gain in five months, compared to a 0.4% decline in the previous month [2][7] Commodity Market - Oil traded down 2% to $64.41, while gold increased by 0.9% to $3,844.30. Silver rose 0.5% to $46.895, and copper gained 0.7% to $4.8070 [4] European Market - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2%, while Spain's IBEX 35 Index fell 0.2%. London's FTSE 100 rose 0.4%, Germany's DAX 40 slipped 0.1%, and France's CAC 40 climbed 0.3% [5] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng gaining 1.89%, China's Shanghai Composite rising 0.90%, and India's BSE Sensex falling 0.08% [6] Stock Performance - Maison Solutions Inc. (NASDAQ: MSS) shares surged 257% to $3.3603, while Predictive Oncology Inc. (NASDAQ: POAI) increased 112% to $1.64 after announcing a 1-for-15 reverse stock split. Maison Solutions Inc. also saw a 167% gain to $2.56 [9] - KALA BIO, Inc. (NASDAQ: KALA) shares dropped 92% to $1.4350 after failing to meet primary endpoints in a clinical trial. MoonLake Immunotherapeutics (NASDAQ: MLTX) shares fell 89% to $6.76 following disappointing trial results, and IO Biotech, Inc. (NASDAQ: IOBT) was down 75% to $0.3941 after an update post-FDA meeting [9]